Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Flaviviruses are arthropod-borne viruses (arboviruses) that have been recently considered among the significant public health problems in defined geographical regions. In this line, there have been vaccines approved for some flaviviruses including dengue virus (DENV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and tick-borne encephalitis virus (TBEV), although the efficiency of such vaccines thought to be questionable. Surprisingly, there are no effective vaccine for many other hazardous flaviviruses, including West Nile and Zika viruses. Furthermore, in spite of approved vaccines for some flaviviruses, for example DENV, alternative prophylactic vaccines seem to be still needed for the protection of a broader population, and it originates from the unsatisfying safety, and the efficacy of vaccines that have been introduced. Thus, adenovirus vector-based vaccine candidates are suggested to be effective, safe, and reliable. Interestingly, recent widespread use of adenovirus vector-based vaccines for the COVID-19 pandemic have highlighted the importance and feasibility of their widespread application. In this review, the applicability of adenovirus vector-based vaccines, as promising approaches to harness the diseases caused by Flaviviruses, is discussed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481145PMC
http://dx.doi.org/10.1080/21645515.2022.2079323DOI Listing

Publication Analysis

Top Keywords

adenovirus vector-based
16
vector-based vaccines
12
vaccines
8
flaviviruses including
8
encephalitis virus
8
flaviviruses
6
adenovirus
4
vaccines forefront
4
forefront approaches
4
approaches fighting
4

Similar Publications

Assessment of the biodistribution and shedding is required for the development of viral vector-based vaccines. Vector copy number is commonly quantified using digital PCR (dPCR) or quantitative PCR (qPCR). However, the regulatory guidelines for bioanalytical PCR assays have not been released at present.

View Article and Find Full Text PDF

[Quantification of viral particles in adenovirus vector-based vaccines by nano-flow cytometry].

Sheng Wu Gong Cheng Xue Bao

August 2025

NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai Institute for Food and Drug Control, Shanghai 201203, China.

This study aims to establish a method for counting the viral particles in adenovirus vector-based vaccines. Nano-flow cytometry was employed to analyze the viral particles in adenovirus-based vector vaccines at the single-particle level. Monodisperse silica nanoparticles with a refractive index close to that of the virus were selected as the particle size standard to calculate the viral particle size, which was then compared with the results obtained from transmission electron microscopy (TEM) to determine the gating strategy.

View Article and Find Full Text PDF

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in over 180 million cases and 4 million deaths by mid-2021. Vaccine hesitancy, particularly among women, stems from limited safety data in vulnerable populations. Therefore, we evaluated the developmental and reproductive safety of AdCLD-CoV19, an adenoviral vector-based coronavirus 2019 (COVID-19) vaccine, in pregnant Sprague-Dawley rats and their offspring.

View Article and Find Full Text PDF

Differentiation of patient-specific induced pluripotent stem cells derived from type 1 diabetes peripheral blood mononuclear cells into pancreatic β-like cells.

World J Stem Cells

July 2025

Fujian Key Laboratory of Medical Analysis, Fujian Academy of Medical Sciences, Fuzhou 350001, Fujian Province, China.

Background: Type 1 diabetes (T1D) results from the autoimmune-mediated loss of pancreatic β-cells. Current insulin therapies offer symptomatic relief but fall short of providing a definitive cure. Islet cell transplantation, while promising, faces limitations related to donor scarcity, procedural complexities, and the necessity for long-term immunosuppression.

View Article and Find Full Text PDF

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve, developing multivalent vaccines becomes crucial to ensure broader immunogenicity against the emerging variants. Traditional multivalent vaccines are produced by combining separately formulated monovalent vaccines in equal proportions, which necessitates precisely quantifying each component. However, the minimal differences in SARS-CoV-2 spike protein sequences among variants pose challenges for immunological quantification methods.

View Article and Find Full Text PDF